Thromboembolic toxicity observed with concurrent trametinib and lenalidomide therapy.
lenalidomide
thromboembolic toxicity
trametinib
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
revised:
12
12
2022
received:
18
05
2022
accepted:
13
12
2022
pmc-release:
01
03
2024
pubmed:
6
1
2023
medline:
27
1
2023
entrez:
5
1
2023
Statut:
ppublish
Résumé
The event-free survival of pediatric low-grade gliomas is poor, and patients often require multiple treatment strategies. While MEK and RAF inhibitors are efficacious in early-phase trials, not all patients respond, and many experience progression following completion of therapy. Evaluating combination therapies that may enhance efficacy or prolong disease stabilization is warranted. We report our institutional experience using concurrent trametinib and lenalidomide in the treatment of primary pediatric central and peripheral nervous system tumors. Two of four patients using this combination therapy experienced severe thromboembolic events, necessitating discontinuation of therapy. This combination requires further investigation, and we urge caution if used.
Identifiants
pubmed: 36602034
doi: 10.1002/pbc.30190
pmc: PMC10519171
mid: NIHMS1928592
doi:
Substances chimiques
Lenalidomide
F0P408N6V4
trametinib
33E86K87QN
Pyridones
0
Pyrimidinones
0
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30190Subventions
Organisme : NINDS NIH HHS
ID : K08 NS121592
Pays : United States
Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
J Clin Oncol. 1993 May;11(5):850-6
pubmed: 8487049
Nat Genet. 2013 Jun;45(6):602-12
pubmed: 23583981
Mayo Clin Proc. 2005 Dec;80(12):1549-51
pubmed: 16350272
Neuro Oncol. 2012 Oct;14(10):1265-84
pubmed: 22942186
Cancer. 2016 Apr 15;122(8):1261-9
pubmed: 26970559
Ann Oncol. 2015 May;26(5):894-901
pubmed: 25722381
J Neurooncol. 2020 Sep;149(3):499-510
pubmed: 33026636
J Neurooncol. 2020 Sep;149(3):437-445
pubmed: 33040274
J Clin Oncol. 2012 Jul 20;30(21):2641-7
pubmed: 22665535
BMC Cancer. 2019 Dec 27;19(1):1250
pubmed: 31881853
J Pediatr Hematol Oncol. 2020 Nov;42(8):e730-e737
pubmed: 32398601
JAMA Netw Open. 2019 Aug 2;2(8):e198890
pubmed: 31397860
Lancet Oncol. 2019 Jul;20(7):1011-1022
pubmed: 31151904
J Neurooncol. 1999 Feb;41(3):255-9
pubmed: 10359145
N Engl J Med. 2012 Jul 12;367(2):107-14
pubmed: 22663011
Pediatr Blood Cancer. 2014 Jul;61(7):1173-9
pubmed: 24482038
J Neurooncol. 2020 Sep;149(2):253-262
pubmed: 32780261
Neuro Oncol. 2017 Aug 01;19(8):1135-1144
pubmed: 28339824
J Neurosurg. 1997 May;86(5):747-54
pubmed: 9126887
Oncogene. 2014 Apr 17;33(16):2019-26
pubmed: 23624918
J Neurooncol. 2020 Jul;148(3):569-575
pubmed: 32506370
Neuro Oncol. 2019 Nov 1;21(Suppl 5):v1-v100
pubmed: 31675094
J Clin Oncol. 2011 Jan 20;29(3):316-23
pubmed: 21149673
Cancer Cell. 2020 Apr 13;37(4):569-583.e5
pubmed: 32289278
Pediatr Blood Cancer. 2010 Sep;55(3):471-7
pubmed: 20535831
J Clin Oncol. 2011 Jan 20;29(3):324-9
pubmed: 21149652
Neuro Oncol. 2010 Jul;12(7):621-30
pubmed: 20156809
J Neurooncol. 2018 Nov;140(2):435-444
pubmed: 30097824